drugset
drugset / Trial / NCT01076530

Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors

NCT01076530 ↗

Phase 1 Completed 27 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating young patients with relapsed or refractory primary brain tumors or spinal cord tumors. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may help temozolomide work better by making tumor cells more sensitive to the drug.

Timeline

Start
2010-02
Primary completion
2012-10
Completion
—

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Vorinostat Small molecule 300 mg/m2 Oral
Background Temozolomide Small molecule 150 mg/m2 Oral

Indications

atypical teratoid rhabdoid tumor central nervous system teratoma childhood brain stem glioma childhood central nervous system germinoma childhood central nervous system mixed germ cell tumor childhood cerebellar astrocytic neoplasm childhood cerebral astrocytoma childhood choroid plexus neoplasm childhood medulloblastoma childhood oligodendroglioma childhood spinal cord tumor craniopharyngioma ependymoblastoma grade II meningioma grade III meningioma medulloepithelioma mixed glioma optic pathway glioma paraganglioma pediatric CNS choriocarcinoma pediatric infratentorial ependymoma pediatric supratentorial ependymoma pineoblastoma subependymal giant cell astrocytoma supratentorial primitive neuroectodermal tumor yolk sac tumor of central nervous system